DUBLIN, April 08, 2022 (Globe Newswire) — “The North America Monoclonal Antibody Market 2020-2030 by Source, Category, Production Type, Application, End User and Country: Trend Forecasting and Growth Opportunities” report added ResearchAndMarkets.com’s Presentation.
The North American monoclonal antibody market is projected to grow 10.4% annually over the forecast period and reach $133.4 billion by 2030, driven by increased incidence of new cancer cases and other diseases, increased aging, increased pharmaceutical R&D spending, Is. Health care expenditure, and the adoption of cost-efficient biosimilar monoclonal antibodies.
This report is based on comprehensive research of the entire North America Monoclonal Antibody market and all its sub-segments through comprehensively detailed classification. In-depth analysis and evaluation is generated from premium primary and secondary information sources with inputs from industry professionals across the value chain. The report is based on the 2017-2019 study and provides projections for 2020 and 2021 to 2030 as the base year for 2019 (the year 2020 is not suitable for a research base due to the COVID-19 outbreak)
In-depth qualitative analysis involves the identification and investigation of the following aspects:
- market structure
- development driver
- restrictions and challenges
- Emerging product trends and market opportunities
- Porter’s Fiver Forces
North America market trend & outlook is forecast in an optimistic, balanced and conservative outlook keeping in view of COVID-19. The balanced (most likely) projection is used to measure the North America Monoclonal Antibody Market in every aspect of classification from source, category, production type, application, end user and country point of view.
On the basis of source, the North America market has been segmented into the following sub-markets with annual revenue ($bn) for 2019-2030 included in each segment.
On the basis of category, the North America market has been segmented into the following sub-markets with annual revenue ($bn) for 2019-2030 included in each segment.
- Branded MABS
- Biosimilar MABS
On the basis of production type, the North America market has been segmented into the following sub-markets with annual revenue ($bn) for 2019-2030 included in each segment.
- in vitro production
- in vivo production
On the basis of application, the North America market has been segmented into the following sub-markets with annual revenue ($bn) for 2019-2030 included in each segment.
- Breast Cancer
- colorectal cancer
- lung cancer
- Ovarian Cancer
- other cancer types
- autoimmune diseases
- inflammatory diseases
- infectious disease
- other applications
By end user, the North America market has been segmented into the following sub-markets with annual revenue ($bn) for 2019-2030 included in each segment.
- research institutes
- other end users
Geographically, the following national/local markets are thoroughly screened:
For each major country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The forecast years also include a breakdown of major national markets by source, application, and end user.
The report also covers the current competitive landscape and projected trend; and profiles key vendors, including market leaders and important emerging players.
Major topics covered:
2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Key Growth Drivers
2.3 Market Constraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Analysis of the Five Forces
North America Market Segmentation by 3 Source
3.1 Market Overview by Source
North America Market Segmentation by 4 Category
4.1 Category Wise Market Overview
4.2 Branded Mabs
4.3 Biosimilar Mabs
Segmentation of the North America Market by 5 Production Types
5.1 Market Overview by Production Type
5.2 In vitro production
Vivo Production 5.3
6 Segmentation of North America Market by Application
6.1 Market Overview by Application
6.2.1 Breast Cancer
6.2.2 Colorectal Cancer
6.2.3 Lung Cancer
6.2.4 Ovarian Cancer
6.2.5 Other types of cancer
6.3 Autoimmune diseases
6.4 Inflammatory diseases
6.5 Infectious diseases
6.6 Other Applications
7 Segmentation of the North America Market by End-User
7.1 Market Overview by End User
7.3 Research Institute
7.4 Other End Users
8 North America Markets 2019-2030 by Country
8.1 Overview of the North America Market
9 Competitive Landscape
9.1 Overview of Major Vendors
9.2 New Product Launches, Partnerships, Investments and M&A
9.3 Company Profile
- Abbott Laboratories
- AbbVie, Inc.
- Amgen Inc.
- AstraZeneca Plc
- bare ego
- Bristol-Myers Squibb Company
- Eli Lilly
- F. Hoffman-La Roche Ltd.
- GlaxoSmithKline Plc
- johnson and johnson
- Merck & Company Inc.
- Mylan NV
- norvatis ag
- Sanofi SA
- related report
For more information about this report, visit https://www.researchandmarkets.com/r/vw6nc9
North American monoclonal antibody market